The US Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) to market Quidel’s Sofia SARS Antigen FIA that delivers results in 15 minutes.

The test can qualitatively detect the nucleocapsid protein antigen of SARS-CoV-2 from anterior nares swab samples from people who are either suspected of Covid-19 by their healthcare provider within first five days of symptom onset.

It can also detect Covid-19 in asymptomatic or other epidemiological reasons to suspect the disease tested twice over two or three days with a gap of at least 24 hours.

Available now without needing a prescription, the simple test demonstrated exceptional performance in five days of symptom onset, with a 96.7% positive result agreement with PCR and 100% negative result agreement.

Quidel noted that routine testing using rapid antigen tests has demonstrated to be effective in Covid-19 diagnosis.

To establish the clinical performance, clinical studies in asymptomatic people undergoing serial testing are progressing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Quidel president and CEO Douglas Bryant said: “FDA’s authorisation opens the door to true democratisation of the benefits of serial testing for both individuals experiencing symptoms and screening of people who may not have symptoms but are actively shedding the virus.

“Broadscale application of our Sofia rapid antigen test for covid-19 screening will catch asymptomatic cases early and limit virus spread.”

Testing using the Sofia rapid antigen test is limited to labs which are CLIA- certified and meet the needs to conduct moderate, high or waived complexity tests.

The Sofia SARS Antigen FIA is authorised for Point of Care (POC) usage.

Last week, the US FDA granted an EUA for Quidel’s new QuickVue At-Home OTC COVID-19 Test to be marketed in the country.